<DOC>
	<DOCNO>NCT02651870</DOCNO>
	<brief_summary>A Phase 3 Trial Evaluate Efficacy Safety Combination Therapy Candesartan Amlodipine Versus Candesartan Monotherapy Hypertensive Patients Inadequately Controlled Candesartan Monotherapy</brief_summary>
	<brief_title>Trial Evaluate Efficacy Safety Combination Therapy Candesartan Amlodipine Versus Candesartan Monotherapy Hypertensive Patients Inadequately Controlled Candesartan Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Age 19 Inadequately control Essential hypertension Screening 1 . Drug naive n't take antihypertensive drug within 2 week prior Visit 1 Mean sitDBP ≥ 95mmHg target arm 2 . Taking antihypertensive drug control Mean sitDBP ≥ 90mmHg target arm Inadequately control 4 week Candesartan 16mg monotherapy Mean sitDBP Visit 2 ≥ 90mmHg target arm Ability provide write informed consent The change mean sitDBP ≥ 10mmHg mean sitSBP ≥ 20mmHg target arm Visit 1 Mean sitDBP ≥ 120mmHg mean sitSBP ≥ 200mmHg target arm Visit 1 Visit 2 Known suspect Stage 2 Hypertension ( aortic coarctation , Primary hyperaldosteronism , renal artery stenosis , pheochromocytoma ) Patient congestive heart failure ( NYHA class III , IV ) Patient unstable angina pectoris , myocardial infarction , Valvular heart disease , arrhythmia ( treatment require ) within 3 month History stroke , cerebral hemorrhage within 6 month Type I Diabetes mellitus , Type II Diabetes mellitus HbA1c &gt; 8.5 % History severe malignant retinopathy AST/ALT &gt; UNL*3 , Serum creatinine &gt; UNL*1.5 , K &gt; 5.5mEq/L Patient acute chronic inflammatory ( treatment require ) status Patient need take antihypertensive drug besides Investigational product Patient must treat medication prohibit concomitant use study period History angioedema relate ACE inhibitor angiotensin II receptor blocker Hypersensitive Candesartan/Amlodipine Patient dependent drug alcohol within 6 month History disability drug ADME , active inflammatory bowel syndrome within 12months , impair pancreatic function , GI bleeding , obstruction urinary tract Patients treat investigational product within 30 day first time take investigational product Women pregnant , breastfeed History malignant tumor within 5 year Not eligible participate study discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hypertension</keyword>
</DOC>